Key facts
- This page summarizes Peter J. Ghiloni's Form 4 filing for cbdMD, Inc. (YCBD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Apr 2022, 16:39.
Peter J. Ghiloni - 11 Mar 2022 Form 4 Insider Report for cbdMD, Inc. (YCBD)
- Reporting relationship
- Director
- Issuer ticker
- YCBD
- Reported as of
- 11 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Apr 2022, 16:39:30 UTC
- Prior SEC filing
- 05 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter Ghiloni
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Peter J. Ghiloni filed Form 4 for cbdMD, Inc. (YCBD) on 19 Apr 2022.
Change
- Previous filing in this sequence was filed on 05 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
YCBD
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +5,000
- Change %
- +1.6%
- Price
- $0.000000
- Shares after
- 310,000
- Date
- 11 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
YCBD
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- Shares
- +30,000
- Change %
- Price
- Shares after
- 30,000
- Date
- 11 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $0.8180
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The restricted stock units vest quarterly in equal increments on June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, subject to continued service as a director of the Issuer on each applicable vesting date. Shares of common stock will be delivered to the Reporting Person upon the vesting of the restricted stock units. The restricted stock units were issued under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022.
Footnote F2
The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning March 11, 2022. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of four non-employee directors. The stock options are fully vested.
Footnote F3
Not applicable.